MERRIMACK PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.1 USD | +0.50% |
|
+0.47% | +12.60% |
Presenter SpeechAnupam Rama (Analysts)Okay, let's go ahead and get started. My name is Anupam ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Companyâs wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +12.60% | 218M | |
| +24.69% | 46.71B | |
| +48.83% | 41.8B | |
| -1.08% | 41.52B | |
| -5.86% | 29.55B | |
| +10.82% | 25.78B | |
| -20.48% | 19.26B | |
| +2.36% | 12.14B | |
| -2.81% | 12.08B | |
| +28.38% | 11.98B |
- Stock Market
- Equities
- MACK Stock
- News Merrimack Pharmaceuticals, Inc.
- Transcript : Merrimack Pharmaceuticals, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-11-2018 09